Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRX-801 plus continuous ultrasound with intravenous alteplase in acute ischemic stroke
2006-005491-40Phase 2Terminated
- Sponsor
- ImaRx Therapeutics, Inc.
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in ischemic stroke comparing MRX-801 + continuous ultrasound + intravenous alteplase with Placebo + intravenous alteplase (2 arms). Primary endpoints: Symptomatic intracranial hemorrhage within 36 hours and Recanalization at 90 minutes. Started Aug 2007; status: terminated.
02
Drugs
MRX-801
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2006-005491-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005491-40.